New Hampshire Gov. Maggie Hassan is asking the U.S. Food and Drug Administration to accelerate its consideration of competing products to the EpiPen after a big increase in cost for the allergy treatment.
Hassan sent a letter to the FDA on Monday asking it to accelerate its review and work to ensure that safe and affordable generic versions of the treatment are able to come to market "as quickly as possible."
Mylan, which makes EpiPen, said it will start selling a cheaper version after absorbing waves of criticism over a list price for the emergency allergy treatment that has grown to $608 for a two-pack, making it unaffordable for many patients without insurance or with high-deductible coverage.
There is currently little competition for EpiPen, but that could change.